LENSAR recurring revenue rises 17%, automated registration targeted by end of first quarter 2027
Key Facts
LENSAR set the end of the first quarter of 2027 as its target for introducing automated registration features, as it reported third-quarter recurring revenue rose to $12.6 million, up 17% year over year. The CEO said on the earnings call that the company expects to roll out the features “by the end of the first quarter of 2027,” while noting the timeline could extend into the start of the second quarter. The technology will enable the system to identify and register the patient’s eye fully automatically, according to the CEO. The timing places the project within the platform’s development roadmap, while the feature remains in development and has not yet been launched. The results also highlight growing reliance on recurring revenue, despite a decline in total revenue during the period.
Recurring revenue was $12.6 million, compared with $10.8 million a year earlier, and its share of total revenue rose to 89% from 75%. Total revenue was $14.1 million, down 1% from $14.3 million in the third quarter of 2025. The company attributed the decline to lower system sales against a strong prior-period comparison, while recurring revenue continued to expand. The divergence reflects different performance among the business’s components in the quarter: growth in recurring revenue against a slight decline in overall sales. The company posted a net loss of $4.7 million, compared with a loss of $3.7 million a year earlier.
Procedure-related revenue rose 17% to $9.2 million, and the number of procedures performed increased 12% to 52,545 compared with the same period a year earlier. The company placed 10 ALLY systems during the quarter, bringing the number of installed ALLY systems to about 225 at the end of September, within a total installed base of about 450 laser systems. Twelve ALLY systems were still awaiting installation on September 30. These figures provide context for the expansion of the installed base alongside growth in procedure volume and related revenue. Adjusted EBITDA was $1.7 million, compared with an adjusted loss of $0.3 million in the third quarter of 2025.
The CEO said the third quarter is typically seasonally slower, with summer holidays, surgery schedules and purchasing decisions affecting the pace of activity. He added that results followed a strong second quarter and declined sequentially, describing the pace as “more moderate.” During the quarter, the company demonstrated its new automated registration capabilities at the American Academy of Ophthalmology’s annual meeting and said the presentation drew interest from surgeons and prospective customers. The early demonstration gives the company an opportunity to gauge user interest ahead of the targeted launch date, based on the CEO’s account of the response at the meeting. The development plan combines automated system alignment with the patient’s eye and an expansion of the procedures the platform can perform.
Management is also working to add capabilities for corneal procedures, including creating LASIK flaps, corneal incisions and other procedures. As for the project to integrate phacoemulsification technology, the CEO said it could take between 18 months and less than two years if the company finds the right partner. He placed other integration projects, including surgical microscope technology, on a longer horizon likely to extend from three to five years. These timelines reflect different stages in the product development roadmap, from the nearer-term automated registration target to more distant integration projects. Management did not attach a final launch date to these projects beyond the timelines it cited.
On liquidity, cash, cash equivalents and investments totaled $12.6 million on September 30, compared with $18.0 million on December 31, 2025. Management projected cash burn of between $1 million and $2 million during the remainder of 2026, citing inventory investment and remaining fees related to the Alcon transaction. It said the company could approach cash breakeven at some point in 2027. LENSAR is scheduled to discuss its results and provide an update on a call on November 10, 2026, at 8:30 a.m. Eastern Time. The expected update puts quarterly performance, platform development plans and liquidity among the main areas investors will be watching.